Physician profile
Ashok Biyani
NPI 1780671032
$1,181,184.81
in general payments reported to CMS, 2019-2025
26 companies · $149K in 2025
The $149K reported for 2025 was more than what 95% of Orthopaedic Surgery of The Spine providers received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195K · 2020: $223K · 2021: $238K · 2022: $136K · 2023: $113K · 2024: $127K · 2025: $149K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $387K · Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $387,304.76 |
| Food and Beverage | $1,153.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $637,505.22 | 2019-2025 | Everest Spinal System, Spinejack |
| Globus Medical, INC. | $435,970.03 | 2019-2025 | Acp, Sable, Creo |
| Vb Spine LLC | $105,965.51 | 2025 | Everest Spinal System |
| Pacira Therapeutics, INC. | $445.24 | 2019-2021 | |
| Medtronic, INC. | $406.42 | 2022-2024 | Catalyft Pl Expandable Interbody System, Unid_pass, Infinity Occipitocervical Upper Thoracic System |
| Medtronic USA, INC. | $127.94 | 2019-2020 | |
| Bioventus LLC | $97.55 | 2019-2025 | Durolane |
| Depuy Synthes Sales INC. | $91.62 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $74.94 | 2020-2024 | Iovera, Zilretta, Exparel |
| Vertex Pharmaceuticals Incorporated | $71.14 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $61.03 | 2019-2025 | Euflexxa |
| Spineology INC. | $54.60 | 2022 | |
| Abbott Laboratories | $41.42 | 2019-2020 | |
| Avanos Medical | $40.60 | 2019-2025 | On-Q Pump and Accessories |
| Heron Therapeutics, INC. | $38.46 | 2022-2023 | Zynrelef |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $32.35 | 2022-2023 | |
| Fidia Pharma USA INC. | $31.77 | 2023-2025 | Hymovis, Triluron |
| Ethicon US, LLC | $23.60 | 2024 | Surgicel Nu-Knit |
| Zimmer Biomet Holdings, INC. | $21.42 | 2025 | Tapestry |
| Si-Bone, INC. | $18.29 | 2019 | |
| Pfizer INC. | $15.63 | 2022 | |
| Convatec INC. | $14.69 | 2019 | |
| Zimvie INC. | $14.07 | 2022 | |
| Endo Pharmaceuticals INC. | $13.60 | 2019 | |
| Heraeus Medical, LLC. | $7.67 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$100,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Biyani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.